325 related articles for article (PubMed ID: 7493614)
1. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
[TBL] [Abstract][Full Text] [Related]
2. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
3. Alteration of neurotensin receptors in MPTP-treated mice.
Tanji H; Araki T; Fujihara K; Nagasawa H; Itoyama Y
Peptides; 1999; 20(7):803-7. PubMed ID: 10477079
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
5. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
6. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
[TBL] [Abstract][Full Text] [Related]
7. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
Neuropharmacology; 1989 Nov; 28(11):1211-6. PubMed ID: 2512516
[TBL] [Abstract][Full Text] [Related]
9. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Jolkkonen J; Jenner P; Marsden CD
Brain Res Mol Brain Res; 1995 Sep; 32(2):297-307. PubMed ID: 7500841
[TBL] [Abstract][Full Text] [Related]
11. Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography.
Javitch JA; Strittmatter SM; Snyder SH
J Neurosci; 1985 Jun; 5(6):1513-21. PubMed ID: 4009243
[TBL] [Abstract][Full Text] [Related]
12. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
[No Abstract] [Full Text] [Related]
13. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
Kunikowska G; Jenner P
Brain Res; 2003 Apr; 968(2):206-18. PubMed ID: 12663090
[TBL] [Abstract][Full Text] [Related]
14. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
Graham WC; Hill DR; Woodruff GN; Sambrook MA; Crossman AR
Neurosci Lett; 1991 Sep; 131(1):129-34. PubMed ID: 1791971
[TBL] [Abstract][Full Text] [Related]
15. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
[TBL] [Abstract][Full Text] [Related]
16. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW; Graybiel AM
Proc Natl Acad Sci U S A; 1992 May; 89(9):3859-63. PubMed ID: 1570304
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
Przedborski S; Levivier M; Jiang H; Ferreira M; Jackson-Lewis V; Donaldson D; Togasaki DM
Neuroscience; 1995 Aug; 67(3):631-47. PubMed ID: 7675192
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
19. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
Chinaglia G; Alvarez FJ; Probst A; Palacios JM
Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
[TBL] [Abstract][Full Text] [Related]
20. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
Tanji H; Araki T; Nagasawa H; Itoyama Y
Brain Res; 1999 Apr; 824(2):224-31. PubMed ID: 10196452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
